Pleconaril

About Curovir

Curovir is a virtual, pre-clinical biotech company targeting a first-in-class antiviral for enteroviruses, a large family of viruses with no approved therapeutics. Its lead candidate, CUR-N399, is a small molecule with a dual mechanism targeting host factor PI4KB, showing broad-spectrum activity against EVs and unexpectedly high potency against RSV. The company operates with a lean, virtual model, supported by founder capital and grants, and is positioning its programs for significant unmet needs in respiratory diseases and pandemic preparedness.

Therapeutic Areas